AKT1 and cancer: ERBB2/ERBB3 mutations are significant in a variety of cancers due to their ability to activate the downstream PI3K/AKT and ERK pathways in tumors, promoting cancer cell proliferation; therefore, they are commonly considered poor prognostic markers42.